Vecima Announces Creation of Office of the CTO and Executive Leadership Changes
20.7.2020 18:50:00 EEST | Business Wire | Press release
Vecima Networks Inc. (TSX: VCM) announced today that it has made several organizational changes across the executive leadership team in alignment with the company’s growth and operational objectives.
Mr. Clay McCreery has been appointed Chief Operating Officer. Mr. McCreery previously served as Chief Revenue Officer for Vecima, as well as managing operations for the Content Delivery & Storage business unit. He joined Vecima through the acquisition of Concurrent Technology in 2017. Prior to joining Concurrent, Mr. McCreery was Senior Vice President of Sales of North America at ARRIS for 14 years. During his tenure there, he helped integrate several key acquisitions enabling ARRIS’ market share growth in Access Technologies, DOCSIS Services, and Content Delivery. “This is a pivotal time for the company and the industries we serve. I am thrilled to be part of an organization with the vision and determination to help our customers transition their networks for next-generation services,” said Mr. McCreery.
Mr. Colin Howlett has been appointed Chief Technology Officer and will lead the newly created Office of the CTO. Mr. Howlett previously served as Vice President of Architecture at Vecima, and his tenure with the company spans 23 years, leading engineering and architecture teams. His technical expertise spans a wide breadth, including wireless, wireline, RF, and software engineering. “Throughout my previous roles at Vecima, the aspect I’ve enjoyed most is partnering with the customers we serve to develop unique and compelling solutions to their technical challenges,” said Mr. Howlett. “I look forward to leading a team of world-class technology experts and industry thought leaders as we expand our reach.”
Mr. Kyle Goodwin has been promoted to SVP & General Manager of the Content Delivery & Storage business unit. Mr. Goodwin previously led Concurrent Technology’s research and development portfolio of products through a time of transition in the service provider industry. Prior to joining Concurrent, he spent time in the telecommunications, financial technology, and insurance industries with Motorola, PrimeRevenue, S1 Corporation, and Aflac. Mr. Goodwin is also a Steering Board Member of the DVB Project, an industry-led consortium defining the global standard for digital television.
Mr. Ryan Nicometo has been promoted to SVP & General Manager of the Video & Broadband Solutions business unit. Mr. Nicometo, who also joined Vecima from the acquisition of Concurrent Technology, brings 21 years of experience in the service provider space to his role. Prior to joining Concurrent, he held leadership roles at ARRIS Group, CCI Systems, and Motorola. While at Motorola and ARRIS, he helped integrate technology and talent from several acquisitions across roles in sales and product management.
Mr. Goodwin and Mr. Nicometo will report to Mr. McCreery in their new roles with the company.
“Both Ryan and Kyle have been key members of the management team and have been significant contributors in the success of the company over the last several years,” said Mr. McCreery.
“I am very excited to have Clay, Colin, Kyle, and Ryan take on expanded roles within the Vecima leadership team as we continue to execute on our strategy to serve our global service provider and broadcast customers with a powerful suite of products and technologies that fuel a more connected world,” said Mr. Sumit Kumar, President and Chief Executive Officer of Vecima. “Vecima is positioned for growth and investing in the futures of the industries we serve.”
About Vecima
Vecima Networks Inc. is a global leader focused on developing integrated hardware and scalable software solutions for broadband access, content delivery and telematics. We enable the world’s leading innovators to advance, connect, entertain, and analyze. We build technologies that transform content delivery and storage, enable high-capacity broadband network access, and streamline data analytics. For more information, please visit our website at www.vecima.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200720005209/en/
Contact information
Vecima Networks
Investor Relations – 250-881-1982
invest@vecima.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin ® Epiduo ® Acne Gel Prescription-to-OTC Switch22.5.2026 19:25:00 EEST | Press release
Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) use in ages 12 years and older, marking a significant Prescription-to-OTC transition in acne care. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522074280/en/ The U.S. FDA approves Differin® Epiduo® Acne Gel Prescription-to-OTC switch This milestone represents yet another example of Galderma’s unique Integrated Dermatology strategy, demonstrating how proven innovations from its Therapeutic Dermatology portfolio can further strengthen its Dermatological Skincare offerings. The Prescription‑to‑OTC transition highlights Galderma’s scale and expertise in successfully commercializing dermatology innovations across the full spectrum of acne care. With the appro
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 17:18:00 EEST | Press release
Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522186975/en/ Adam Plich, CEO and Co-Founder of Avanzanite Bioscience. “Thalassaemia is a complex, chronic and multisystem disease characterised by anaemia, ineffective erythropoiesis and haemo
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 15:30:00 EEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu ® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 15:00:00 EEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 14:45:00 EEST | Press release
Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, signalling a shift in health systems from late-stage treatment to earlier intervention. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522587414/en/ Selected from 393 submissions across 68 countries, the winning teams were recognised through the inaugural ‘Future Health Challenge 2026: Building Anticipatory Health Systems through Population Sensing’, delivered by Future Health – A Global Initiative by Abu Dhabi in collaboration with MIT Solve. Health systems globally are facing rising costs and persistent delays in diagnosis, with many conditions still identified only after symptoms become severe. At the sam
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom